{ "items": [ "\n\n
\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n30 March 2020
\n \n \n \nThe problem of substandard and falsified (SF) medical products affects all countries but few regulatory authorities or pharmaceutical companies have policies of publicly releasing data. As a first step in tracking this global issue, IDDO\u2019s Medicine Quality Research Group, with the MORU Tropical Health Network and supported by a grant from the Wellcome Trust, has today launched a new, free-to-use, online tool, the Medicine Quality Monitoring Globe, (MQM Globe) which maps SF news reports worldwide in real time.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n23 March 2020
\n \n \n \nOxford Nuffield Department of Population Health started a new trial of potential treatments for adults patients hospitalised with confirmed COVID-19 with the collaboration of Professor Peter Horby
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n13 March 2020
\n \n \n \nNDM is prioritising collaborative projects for front line actions to support global efforts in tackling nCoV. ISARIC has launched a number of international resources available free of charge, through which investigators retain full control of data and samples. Gavin Screaton and Guy Thwaites are looking at neutralising antibody responses. Other NDM researchers work on vaccine development, structure, protective immune response, UK hospital settings and pathogens evolution.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n28 February 2020
\n \n \n \nA statistical analysis of WWARN data from 4,214 participants across multiple study sites in Africa has been published in BMC Medicine. Results indicate that the local prevalence of resistance-associated markers should be considered when choosing a first-line drug to ensure optimal duration of protection.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n13 February 2020
\n \n \n \nWhat do a mathematician, an epidemiologist, a vaccine developer, a protein crystallographer and a whole bevy of immunologists and infectious disease specialists have in common? Answer: they\u2019re just some of the Oxford University researchers coming together to fight the novel Coronavirus outbreak. Science blog by Charvy Narain
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n31 January 2020
\n \n \n \nIn response the novel coronavirus emergency, the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has activated its Clinical Characterisation Protocol (CCP) for emerging infections in England and Scotland.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n30 January 2020
\n \n \n \nPolicy makers are interested in practical steps to a more gender-equitable and transformative health system. A guide published by Research in Gender & Ethics aims to help policy makers adopt a gender lens in policy deliberations on health systems. In order to prompt reflections on how gender affects health systems, we include case studies from Cambodia, Democratic Republic of Congo, Kenya, Liberia, Malawi, Sierra Leone, South Africa, Tanzania and Uganda.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n28 January 2020
\n \n \n \nGovernments, funders, and research bodies must take action to ensure that research is undertaken ethically during global health emergencies, says a new report from the Nuffield Council on Bioethics.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n17 January 2020
\n \n \n \nA specialist technique used to study drugs has been completed for the first time during an outbreak of Ebola virus disease.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n23 December 2019
\n \n \n \nA new study conducted by Christiane Dolecek and colleagues analysed data on antimicrobial resistance of the bacteria Salmonella Typhi and Salmonella Paratyphi, from around the globe, spanning the time from 1990 to 2018. The study highlights the impact of drug resistance and the urgent need for interventions.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n18 December 2019
\n \n \n \nScience Blog - George Busby of Oxford University's Big Data Institute discusses his team's research into human genetic resistance to malaria and humanity's age-old struggle against the disease.
\n \n\n \n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n
\n \n\n \n11 December 2019
\n \n \n \nA large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting. OUCRU-Nepal Professor Buddha Basnyat took part in this study.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n14 November 2019
\n \n \n \nLife-saving Instruction for Emergences (LIFE), a virtual reality (VR) medical training platform developed by doctors, nurses and researchers at the KEMRI-Wellcome Trust Research Programme (KWTRP) in Kenya and Oxford University with support from HTC, has officially launched today. This new virtual reality medical training app uses HTC VIVE Focus Plus for training doctors and nurses to save lives.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n8 October 2019
\n \n \n \nAn individual patient data meta-analysis of 2,017 patients from 19 studies has found a high risk of recurrence following treatment of P. vivax malaria with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) unless they are co-administered with primaquine. The research supports recommendations that these artemisinin-based combination therapies (ACT) should be combined with primaquine.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n4 October 2019
\n \n \n \nThe Oxford based OHSCAR team is delighted to be a partner the NEST360 project working with KEMRI-Wellcome and the Kenya Paediatric Research Consortium in Kenya to support this effort to improve care care of the sick newborn and save lives
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n18 September 2019
\n \n \n \nThis report presents research on the current state of governance and coordination of health emergency preparedness and response. It highlights key challenges to address for the future. The report was commissioned by the Global Preparedness Monitoring Board to inform their inaugural report launched on 18th September 2019.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n18 September 2019
\n \n \n \nIn partnership with the Wellcome Innovations Flagship Programme, MORU launched its Critical Care Asia Network project with its first investigators\u2019 meeting on 19-20 Aug in Bangkok. The project will establish an Asian ICU network across 42 ICUs in nine countries and implement a setting-adapted electronic registry.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n13 September 2019
\n \n \n \nIn Kenya, the poorest of the poor carry the highest burden of disease. From locally-made, low-cost herbal remedies to affordable hard floors for households, researchers and communities are developing new ways to deal with jiggers in Kenya. Lynne Elson, a research fellow at KEMRI Wellcome Trust, lead a study to determine whether neem and coconut oil reduce inflammation, pain and itching better than the standard treatment in seven days.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n8 September 2019
\n \n \n \nHuman trials of new antimalarial drugs are in the pipeline after KEMRI scientists successfully used bacteria to kill the parasite that causes the disease. Trials in Burkina Faso showed that Ivermectin, a conventional drug used for parasitic diseases including river blindness and elephantiasis, reduced transmission rates. The medication worked by making the blood of people who were repeatedly vaccinated lethal to mosquitoes. The study also found that Ivermectin can kill plasmodium falciparum, the malaria parasite carried by female mosquitoes, when administered to humans.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n7 August 2019
\n \n \n \nIDDO has launched a new global Chagas scientific collaboration with the Drugs for Neglected Diseases initiative (DNDi). The new platform will collate and standardise data to accelerate better treatments for the 6\u20137 million people worldwide with Chagas disease.
\n \n\n \n \n